Valneva
Chemicals & Related Products · France · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
6 Rue Alain Bombard, Saint-Herblain, Pay...Phone Number
+33 228073710Website
www.valneva.comRevenue
$228.2 MillionStock Symbol
VLAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Valneva
Valneva is a biotechnology company founded in 2012 and headquartered in France that specializes in the development and manufacturing of vaccines for infectious diseases. The company focuses on creating innovative preventative solutions in the pharmaceutical and chemical manufacturing sectors. With operations across Europe including France, Sweden, and the United Kingdom, Valneva maintains a global presence in the healthcare industry. The company is publicly traded and combines scientific research with commercial vaccine production to address public health challenges.Explore more
Valneva Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Valneva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Valneva is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Valneva recently announced quarterly report
Product Launch: Get notified when Valneva launches new products
Valneva, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Valneva has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Valneva
Click to see if Valneva had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Valneva has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Valneva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Valneva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Valneva.
Valneva financials insights
Gather financial insights about Valneva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$27.6M
2020
Debt
$100M
2022
Grant
$27.2M
Corporate Investment
$95M
2025
Debt
$500M
Valneva Tech Stack
A closer look at the technologies used by Valneva
See more technologies
Most Recent Scoops
Earnings
Valneva has reported approximately EUR 17 million in other revenues for fiscal year 2025, an increase compared to the prior year, primarily reflecting the recognition of previously deferred revenue associated with its Lyme disease vaccine development contract with Pfizer, with no impact on cash liquidity.
Earnings, Pharmaceuticals, Finance
Earnings
Valneva has reported sales of EUR 8.4 million for IXCHIQ, its chikungunya vaccine, in fiscal year 2025, which includes deliveries made to Réunion in response to a chikungunya outbreak earlier in the year.
Sales, Pharmaceuticals
Earnings
Valneva has reported that sales of DUKORAL, its cholera vaccine, declined by 1.2% in fiscal year 2025 compared to the prior year, primarily due to a distributor change in Germany that impacted inventory levels. Valneva expects a return to growth for DUKORAL going forward.
Earnings
Valneva has reported total revenue of EUR 174 million and cost of goods and services of EUR 107 million for fiscal year 2025, with the year-over-year increase in costs primarily attributable to IXCHIQ inventory write-downs and the activation of its new production facility in Livingston, Scotland.
Earnings, Logistics / Supply Chain, Inventory Management, Finance, Manufacturing Operations
Person-Based
Marketing Campaign
Valneva News & Media
Valneva Announces Successful Outcome of its Annual General Meeting
Dr. Gerd Zettlmeissl is appointed as Chair of the Board of DirectorsValneva Announces Availability of Documentation for its Annual General Meeting
Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meeting (“the Meeting”) to be held on June 25, 2026 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France).Valneva to Participate at U.S. and European Investor Conferences in June
Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026.Valneva to lay off up to 15%, faces tough travel vaccine market - Fierce Biotech
Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs. | Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Valneva
Sign Up For FreeTo access detailed company insights
Valneva is a biotechnology company founded in 2012 and headquartered in France that specializes in the development and manufacturing of vaccines for infectious diseases. The company focuses on creating innovative preventative solutions in the pharmaceutical and chemical manufacturing sectors. With operations across Europe including France, Sweden,... Read More
